Table: Aska Pharmaceutical Holdings -2022/23 group results

ASKA Pharmaceutical Holdings

11/05/2023 07:00

May 11 (Reuters)- 
          Aska Pharmaceutical Holdings Co., Ltd. 
          CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended       Year to       NEXT   
              Mar 31, 2023    Mar 31, 2022   Mar 31, 2024     YEAR     
                 LATEST         YEAR-AGO        COMPANY      COMPANY   
                 RESULTS         RESULTS       FORECAST    H1 FORECAST 
  Sales           60.46           56.61          62.00                 
               (+6.8 pct)                     (+2.5 pct)               
  Operating        5.11            4.80           5.40                 
               (+6.5 pct)                     (+5.7 pct)               
  Recurring        5.23            4.88           5.50                 
               (+7.2 pct)                     (+5.1 pct)               
  Net
  Net              4.24            4.29           4.40                 
               (-1.2 pct)                     (+3.8 pct)               
  EPS          150.08 yen      151.22 yen     155.81 yen               
  Ann Div       16.00 yen       15.00 yen      20.00 yen               
  -Q2 Div       8.00 yen        7.00 yen       10.00 yen               
  -Q4 Div       8.00 yen        8.00 yen       10.00 yen               
  
  NOTE - Aska Pharmaceutical Holdings Co., Ltd..
  *Second Net profit row denotes profit attributable to owners ofthe parent 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4886.T